Menu
Innovation Observatory > Reports > Drugs > Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line

< Back

Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line

Drugs

Cancer and Palliative Care

July 2017


Pembrolizumab is an intravenously administered drug that is already approved for use in other types of cancers. It is now explored in a clinical trial as an initial (first line) treatment option for people diagnosed with advanced gastric or gastroesophageal adenocarcinomas. If licensed for use in the UK, pembrolizumab would provide a new treatment option for patients who currently have a poor life expectancy and few treatment options.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts